Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4565 On Other Exchanges
Symbol
Exchange
4565 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sosei group corp (4565) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOSEI GROUP CORP (4565)

Related News

No related news articles were found.

sosei group corp (4565) Related Businessweek News

No Related Businessweek News Found

sosei group corp (4565) Details

Sosei Group Corporation, a biopharmaceutical company, develops and commercializes pharmaceutical products worldwide. The company offers NorLevo, an oral emergency contraceptive pill. Its product pipeline includes Seebri/NVA237, an inhaled long-acting muscarinic antagonist indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD); and Ultibro/QVA149, an inhalation capsules for the maintenance bronchodilator treatment of COPD. The company’s product pipeline comprises SO-1105, an antifungal agent, which in Phase III clinical trial for the treatment of oropharyngeal candidiasis in immunocompromised patients; and APP13002 and APP13007, which are in pre-clinical stage for infectious cornea and conjunctivitis, and inflammation. In addition, it develops Molecular Hiving, a liquid-phase peptide synthesis technology; Peptune, a novel peptide modification technology; and stabilized receptor technology that produces agents acting on G protein-coupled receptors. Further, the company develops QVM149, an inhaled triple therapy for uncontrolled asthma. Sosei Group Corporation was incorporated in 1990 and is headquartered in Tokyo, Japan.

Founded in 1990

sosei group corp (4565) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sosei group corp (4565) Key Developments

Sosei Group Corporation Announces Executive Changes

Sosei Group Corporation announced the following new appointments and changes. Effective as of 23 June 2015: Malcolm Weir, Heptares Therapeutics, CEO appointed as Executive Vice President, Chief R&D Officer Heptares Therapeutics, CEO; Fiona Marshall, Heptares Therapeutics, CSO as Executive Vice President, CSO and Heptares Therapeutics, CSO; Akinori Mochizuki, Executive Vice President, CSO now appointed as Chief Technical Officer and departure of Hiromu Ozaki, Executive Vice President, Representative Director of Sosei K.K.

Sosei Group Corporation Announces Two Positive US Phase III Programs in COPD for QVA149 and NVA237

Sosei Group Corporation announced by Novartis from two pivotal Phase III clinical trial programs for QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). The EXPEDITION (including FLIGHT 1, 2 and 3 studies) and GEM programs met their primary and secondary endpoints, and the results were presented for the first time at the ATS International Conference, 15-20 May 2015, in Denver, US. Data from the EXPEDITION program demonstrated that QVA149, administered twice-daily, improved lung function (FEV1 AUC0-12h) compared to placebo and its individual monocomponents, indacaterol and glycopyrronium bromide (p<0.001), after 12 weeks of treatment, meeting its primary objective1-2. Further findings also confirmed that Novartis' dual bronchodilator improved breathlessness, overall quality of life and COPD rescue medication use. It also showed significant improvements in FEV1 at 5 min and 15 min compared to placebo according to new pooled data from over 2,000 patients.

Sosei Group Corporation Announces Consolidated and Non-Consolidated Earnings Results for the Full Year Ended March 31, 2015; Provides Earnings Guidance for the Financial Year Ending March 31, 2016

Sosei Group Corporation announced consolidated and non-consolidated earnings results for the full year ended March 31, 2015. For the year, on consolidated basis, the company reported revenue of ¥3,671,309,000 against ¥2,069,836,000 a year ago. Operating income was ¥1,108,848,000 against ¥756,393,000 a year ago. Ordinary loss was ¥1,065,917,000 against ¥788,137,000 a year ago. Net loss before income taxes was ¥1,366,635,000 against ¥737,848,000 a year ago. Net income was ¥562,522,000 or ¥40.89 diluted per share against ¥737,848,000 or ¥124.89 diluted per share a year ago. Comprehensive income was ¥263,202,000 against ¥1,685,920,000 a year ago. Net cash provided by operating activities was ¥92,570,000 against ¥363,279,000 a year ago. Purchase of property, plant and equipment was ¥88,890,000 against ¥10,521,000 a year ago. The company provided earnings guidance for the financial year ending March 31, 2016. For the year, the company revenue of ¥11,732 million, operating income of ¥5,899 million, income before income tax of ¥5,915 million and net income attributable to owners of the parent company of ¥6,047 million or ¥145.46 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4565:JP ¥7,020.00 JPY -160.00

4565 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4565.
View Industry Companies
 

Industry Analysis

4565

Industry Average

Valuation 4565 Industry Range
Price/Earnings 100.0x
Price/Sales 25.8x
Price/Book 6.5x
Price/Cash Flow 166.5x
TEV/Sales 18.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOSEI GROUP CORP, please visit www.sosei.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.